89 results match your criteria Biomarkers in cancer[Journal]


Vasodilator-Stimulated Phosphoprotein Biomarkers Are Associated with Invasion and Metastasis in Colorectal Cancer.

Biomark Cancer 2018 5;10:1179299X18774551. Epub 2018 Jun 5.

BioDetego LLC, Philadelphia, PA, USA.

Background And Aims: The benefit of adjuvant chemotherapy for stage II colorectal cancer (CRC) patients remains unclear, emphasizing the need for improved prognostic biomarkers to identify patients at risk of metastatic recurrence. To address this unmet clinical need, we examined the expression and phosphorylation status of the vasodilator-stimulated phosphoprotein (VASP) in CRC tumor progression. VASP, a processive actin polymerase, promotes the formation of invasive membrane structures leading to extracellular matrix remodeling and tumor invasion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X18774551DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419247PMC

RBBP6 Is Abundantly Expressed in Human Cervical Carcinoma and May Be Implicated in Its Malignant Progression.

Biomark Cancer 2019 11;11:1179299X19829149. Epub 2019 Mar 11.

Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, Sovenga, South Africa.

RBBP6 is a novel gene encoding splicing-associated proteins. There are 3 protein isoforms (isoforms 1-3). RBBP6 isoforms 1 has been shown to interact with both p53 and Rb. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X19829149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415476PMC

Urine Biomarkers for the Early Detection of Ovarian Cancer - Are We There Yet?

Biomark Cancer 2019 26;11:1179299X19830977. Epub 2019 Feb 26.

Department of Biomedical Sciences, University of Hull, Hull, UK.

Ovarian cancer affects around 7500 women in the United Kingdom every year. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; however, there is usually a masking of symptoms which leads to an often late-stage diagnosis and correspondingly poor survival rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X19830977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393943PMC
February 2019

Corrigendum.

Authors:

Biomark Cancer 2018 14;10:1179299X18819148. Epub 2018 Dec 14.

[This corrects the article DOI: 10.1177/1179299X17737301.]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X18819148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295673PMC
December 2018

Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study.

Biomark Cancer 2018 18;10:1179299X18781095. Epub 2018 Jun 18.

University of Namur, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Department of Pharmacy, Namur, Belgium.

Objectives: Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous in terms of phenotype and treatment response in patients. These characteristics make the prognosis difficult to establish and hinder the use of new personalized treatments in clinical practice. In this context, there is currently a need to define new biomarkers enabling a better definition of DLBCL subtypes, prognosis evaluation, and an overview of the resistance to chemotherapeutics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X18781095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024490PMC

Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers?

Biomark Cancer 2018 30;10:1179299X18776974. Epub 2018 May 30.

Department of Surgical Gastroenterology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.

Introduction: Most of the subjects undergoing diagnostic colonoscopy do not have neoplastic bowel lesions. Potentially, some of the symptoms may therefore be caused by extracolonic malignancy, and subjects with persisting symptoms may need subsequent examinations. Blood-based, cancer-associated biomarkers may aid in directing the examinations for other specific malignant diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X18776974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977429PMC
May 2018
1 Read

Data Mining of Small RNA-Seq Suggests an Association Between Prostate Cancer and Altered Abundance of 5' Transfer RNA Halves in Seminal Fluid and Prostatic Tissues.

Biomark Cancer 2018 20;10:1179299X18759545. Epub 2018 Feb 20.

Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.

Extracellular RNAs are gaining clinical interest as biofluid-based noninvasive markers for diseases, especially cancer. In particular, derivatives of transfer RNA (tRNA) are emerging as a new class of small-noncoding RNAs with high biomarker potential. We and others previously reported alterations in serum levels of specific tRNA halves in disease states including cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X18759545DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824904PMC
February 2018
1 Read

Integrating Circulating Immunological and Sputum Biomarkers for the Early Detection of Lung Cancer.

Biomark Cancer 2018 13;10:1179299X18759297. Epub 2018 Feb 13.

Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.

We have demonstrated that assessments of microRNA (miRNA) expressions in circulating peripheral blood mononucleated cell (PBMC) and sputum specimens, respectively, may help diagnose lung cancer. To assess the individual and combined analysis of the miRNAs across the different body fluids for lung cancer early detection, we analyse a panel of 3 sputum miRNAs (miRs-21, 31, and 210) and a panel of 2 PBMC miRNAs (miRs-19b-3p and 29b-3p) in a discovery cohort of 68 patients with lung cancer and 66 cancer-free smokers. We find that integrating 2 sputum miRNAs (miRs-31 and 210) and 1 PBMC miRNA (miR-19b-3p) has higher sensitivity (86. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X18759297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815414PMC
February 2018
8 Reads

HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder Cancer.

Biomark Cancer 2018 8;10:1179299X17751920. Epub 2018 Jan 8.

Institute for Science and Technology in Medicine, Keele University, London, UK.

Background: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery. Molecular biomarkers, particularly DNA methylation, have been reported as predictive of tumour/patient outcomes in numerous solid organ and haematologic malignancies; however, there are few reports in HR-NMIBC and none using genome-wide array assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X17751920DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764140PMC
January 2018
6 Reads

Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma.

Biomark Cancer 2017 2;9:1179299X17737301. Epub 2017 Nov 2.

Department of Hepatology, Loyola University Chicago, Chicago, IL, USA.

Hepatocellular carcinoma (HCC) is a major malignancy in the liver and has emerged as one of the main cancers in the world with a high mortality rate. However, the molecular mechanisms of HCC are still poorly understood. Long noncoding RNAs (lncRNAs) have recently come to the forefront as functional non-protein-coding RNAs that are involved in a variety of cellular processes ranging from maintaining the structural integrity of chromosomes to gene expression regulation in a spatiotemporal manner. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1179299X17737301
Publisher Site
http://dx.doi.org/10.1177/1179299X17737301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673005PMC
November 2017
2 Reads

More Accurate Oral Cancer Screening with Fewer Salivary Biomarkers.

Biomark Cancer 2017 17;9:1179299X17732007. Epub 2017 Oct 17.

Department of Oral Diagnostic and Surgical Sciences, School of Dentistry, International Medical University (IMU), Kuala Lumpur, Malaysia.

Signal detection and Bayesian inferential tools were applied to salivary biomarkers to improve screening accuracy and efficiency in detecting oral squamous cell carcinoma (OSCC). Potential cancer biomarkers are identified by significant differences in assay concentrations, receiver operating characteristic areas under the curve (AUCs), sensitivity, and specificity. However, the end goal is to report to individual patients their risk of having disease given positive or negative test results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X17732007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648090PMC
October 2017
3 Reads

In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer.

Biomark Cancer 2017 28;9:1179299X17728254. Epub 2017 Aug 28.

Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Peritoneal metastasis (PM) occurs in about 10% of patients with colorectal cancer (CRC). Fluorescence imaging can enhance contrast between cancerous and benign tissue, enabling the surgeon to clearly visualize PM during cytoreductive surgery. This study assessed the suitability of different biomarkers as potential targets for tumor-targeted imaging of PM of CRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X17728254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576539PMC
August 2017
13 Reads

Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank.

Biomark Cancer 2017 30;9:1179299X17710944. Epub 2017 May 30.

School of Biochemistry, University of Bristol, Bristol, UK.

Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X17710944DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457026PMC
May 2017
4 Reads

Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.

Biomark Cancer 2017 17;9:1179299X17710016. Epub 2017 May 17.

Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Carcinoembryonic antigen (CEA)-targeted imaging and therapeutic agents are being tested in clinical trials. If CEA overexpression in malignant tissue corresponds with elevated serum CEA, serum CEA could assist in selecting patients who may benefit from CEA-targeted agents. This study aims to assess the relationship between serum CEA and CEA expression in pancreatic (n = 20) and rectal cancer tissues (n = 35) using histopathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X17710016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437985PMC
May 2017
1 Read

Biomarkers for Hepatocellular Carcinoma.

Biomark Cancer 2017 28;9:1-9. Epub 2017 Feb 28.

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis prediction. Furthermore, it might represent certain therapeutic interventions through some combinations of biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X16684640DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345949PMC
February 2017
4 Reads

Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers.

Biomark Cancer 2017 16;9:1-7. Epub 2017 Feb 16.

Department of Clinical Biochemistry, State Key Laboratory of Kidney Disease, Chinese PLA General Hospital, Beijing, China.

Background: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors.

Objective: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment.

Methods: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179299X17690142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345947PMC
February 2017
3 Reads

miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma.

Biomark Cancer 2017 9;9:1-8. Epub 2017 Jan 9.

Center for Molecular Biology of Oral Diseases, Department of Periodontics, College of Dentistry, University of Illinois at Chicago, Chicago, IL, USA.; UIC Cancer Center, Graduate College, University of Illinois at Chicago, Chicago, IL, USA.

Oral tongue squamous cell carcinoma (TSCC) is a complex disease with extensive genetic and epigenetic defects, including microRNA deregulation. The aims of the present study were to test the feasibility of performing the microRNA profiling analysis on archived TSCC specimens and to assess the potential diagnostic utility of the identified microRNA biomarkers for the detection of TSCC. TaqMan array-based microRNA profiling analysis was performed on 10 archived TSCC samples and their matching normal tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S40981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224348PMC
January 2017
8 Reads
5 Citations

Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Biomark Cancer 2016 27;8:119-133. Epub 2016 Sep 27.

Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.; Antibodies for Research Applications BV, Gouda, the Netherlands.

Tumor targeting is a booming business: The global therapeutic monoclonal antibody market accounted for more than $78 billion in 2012 and is expanding exponentially. Tumors can be targeted with an extensive arsenal of monoclonal antibodies, ligand proteins, peptides, RNAs, and small molecules. In addition to therapeutic targeting, some of these compounds can also be applied for tumor visualization before or during surgery, after conjugation with radionuclides and/or near-infrared fluorescent dyes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S38542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040425PMC
September 2016
6 Reads
7 Citations

Association of (C677T) Gene Polymorphism With Breast Cancer in North India.

Biomark Cancer 2016 27;8:111-117. Epub 2016 Sep 27.

Molecular Cell Biology Laboratory, Department of Biochemistry, King George's Medical University, Lucknow, Uttar Pradesh, India.

Background: Breast cancer is one of the most common malignancies in women and is associated with a variety of risk factors. The functional single-nucleotide polymorphism (SNP) C677T in the gene encoding 5,10-methylenetetrahydrofolate reductase () may lead to decreased enzyme activity and affect the chemosensitivity of tumor cells. This study was designed to investigate the association of gene polymorphism (SNP) in the pathogenesis of breast cancer among the North Indian women population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S40446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040218PMC
September 2016
25 Reads
2 Citations

PET Metabolic Biomarkers for Cancer.

Biomark Cancer 2016 20;8(Suppl 2):61-9. Epub 2016 Sep 20.

National Cardiac PET Centre, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.

The body's main fuel sources are fats, carbohydrates (glucose), proteins, and ketone bodies. It is well known that an important hallmark of cancer cells is the overconsumption of glucose. Positron emission tomography (PET) imaging using the glucose analog (18)F-fluorodeoxyglucose ((18)F-FDG) has been a powerful cancer diagnostic tool for many decades. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030827PMC
http://dx.doi.org/10.4137/BIC.S27483DOI Listing
September 2016
3 Reads

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition.

Biomark Cancer 2016 28;8:101-10. Epub 2016 Jul 28.

NUMPEX-BIO, Campus Xerém, Federal University of Rio de Janeiro, Duque de Caxias, Rio de Janeiro, Brazil.; Institute for Translational Research on Health and Environment in the Amazon Region-INPeTAm, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

The transforming properties of oncogenes are derived from gain-of-function mutations, shifting cell signaling from highly regulated homeostatic to an uncontrolled oncogenic state, with the contribution of the inactivating mutations in tumor suppressor genes P53 and RB, leading to tumor resistance to conventional and target-directed therapy. On the other hand, this scenario fulfills two requirements for oncolytic virus infection in tumor cells: inactivation of tumor suppressors and presence of oncoproteins, also the requirements to engage malignancy. Several of these oncogenes have a negative impact on the main interferon antiviral defense, the double-stranded RNA-activated protein kinase (PKR), which helps viruses to spontaneously target tumor cells instead of normal cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S33378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966488PMC

Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images.

Biomark Cancer 2016 3;8(Suppl 2):47-59. Epub 2016 Jul 3.

Department of Radiology, University of Calgary, Calgary, AB, Canada.; Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.; Seaman Family MR Centre, Foothills Medical Centre, Calgary, AB, Canada.

Dynamic contrast-enhanced perfusion and permeability imaging, using computed tomography and magnetic resonance systems, are important techniques for assessing the vascular supply and hemodynamics of healthy brain parenchyma and tumors. These techniques can measure blood flow, blood volume, and blood-brain barrier permeability surface area product and, thus, may provide information complementary to clinical and pathological assessments. These have been used as biomarkers to enhance the treatment planning process, to optimize treatment decision-making, and to enable monitoring of the treatment noninvasively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S31801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933536PMC
July 2016
3 Reads

Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.

Biomark Cancer 2016 4;8(Suppl 1):37-55. Epub 2016 Jul 4.

Pfizer Clinical Research Unit, New Haven CT, USA.

Hepatocellular carcinoma (HCC), one of the leading causes of cancer deaths in the world, is offering a challenge to human beings, with the current modes of treatment being a palliative approach. Lack of proper curative or preventive treatment methods encouraged extensive research around the world with an aim to detect a vaccine or therapeutic target biomolecule that could lead to development of a drug or vaccine against HCC. Biomarkers or biological disease markers have emerged as a potential tool as drug/vaccine targets, as they can accurately diagnose, predict, and even prevent the diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S34413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933537PMC
July 2016
4 Reads

Predicting Clinical Outcomes Using Molecular Biomarkers.

Authors:
Harry B Burke

Biomark Cancer 2016 6;8:89-99. Epub 2016 Jun 6.

Professor of Medicine, Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Over the past 20 years, there has been an exponential increase in the number of biomarkers. At the last count, there were 768,259 papers indexed in PubMed.gov directly related to biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S33380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896533PMC

The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy.

Biomark Cancer 2016 23;8(Suppl 2):39-45. Epub 2016 May 23.

Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.

With the improvement of cancer therapy, survival related to malignancy has improved, but the prevalence of long-term cardiotoxicity has also increased. Cancer therapies with known cardiac toxicity include anthracyclines, biologic agents (trastuzumab), and multikinase inhibitors (sunitinib). The most frequent presentation of cardiac toxicity is dilated cardiomyopathy associated with poorest prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S31798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878717PMC
June 2016
5 Reads

Targeted Radionuclide Therapy: Practical Applications and Future Prospects.

Biomark Cancer 2016 18;8(Suppl 2):35-8. Epub 2016 May 18.

Department of Radiology, Boston Children's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.

In recent years, there has been a proliferation in the development of targeted radionuclide cancer therapy. It is now possible to use baseline clinical and imaging assessments to determine the most effective therapy and to tailor this therapy during the course of treatment based on radiation dosimetry and tumor response. Although this personalized approach to medicine has the advantage of maximizing therapeutic effect while limiting toxicity, it can be challenging to implement and expensive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S31804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874742PMC
May 2016
8 Reads

Impact of Concanavalin-A-Mediated Cytoskeleton Disruption on Low-Density Lipoprotein Receptor-Related Protein-1 Internalization and Cell Surface Expression in Glioblastomas.

Biomark Cancer 2016 19;8:77-87. Epub 2016 May 19.

Laboratoire d'Oncologie Moléculaire, Centre de recherche BIOMED, Département de Chimie, Université du Québec à Montréal, QC, Canada.

The low-density lipoprotein receptor-related protein 1 (LRP-1) is a multiligand endocytic receptor, which plays a pivotal role in controlling cytoskeleton dynamics during cancer cell migration. Its rapid endocytosis further allows efficient clearance of extracellular ligands. Concanavalin-A (ConA) is a lectin used to trigger in vitro physiological cellular processes, including cytokines secretion, nitric oxide production, and T-lymphocytes activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S38894DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874747PMC
May 2016
13 Reads

The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.

Biomark Cancer 2016 5;8(Suppl 2):15-33. Epub 2016 May 5.

Professor and Chief of Urology, CHUM-Pavillon R, Montreal, QC, Canada.

Prostate cancer (PC) is the second most common form of cancer in men worldwide. Biomarkers have emerged as essential tools for treatment and assessment since the variability of disease behavior, the cost and diversity of treatments, and the related impairment of quality of life have given rise to a need for a personalized approach. High-throughput technology platforms in proteomics and genomics have accelerated the development of biomarkers. Read More

View Article

Download full-text PDF

Source
http://www.la-press.com/redirect_file.php?fileId=7459&filena
Web Search
http://www.la-press.com/the-present-and-future-of-biomarkers
Publisher Site
http://dx.doi.org/10.4137/BIC.S31802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859450PMC
May 2016
28 Reads

BMI1: A Biomarker of Hematologic Malignancies.

Biomark Cancer 2016 5;8:65-75. Epub 2016 May 5.

Department of Biotechnology, Pandit Ravishankar Shukla University, Chhattisgarh, India.

BMI1 oncogene is a catalytic member of epigenetic repressor polycomb group proteins. It plays a critical role in the regulation of gene expression pattern and consequently several cellular processes during development, including cell cycle progression, senescence, aging, apoptosis, angiogenesis, and importantly self-renewal of adult stem cells of several lineages. Preponderance of evidences indicates that deregulated expression of PcG protein BMI1 is associated with several human malignancies, cancer stem cell maintenance, and propagation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S33376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859448PMC
May 2016
2 Reads

Biomarkers and Targeted Therapy in Pancreatic Cancer.

Biomark Cancer 2016 26;8(Suppl 1):27-35. Epub 2016 Apr 26.

Department of Pharmaceutical Sciences, College of Health Professions, North Dakota State University, Fargo, ND, USA.

Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%-3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal type, altered drug delivery, and drug resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BiC.s34414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847554PMC
May 2016
53 Reads

Assessment of Cytokeratin-19 Gene Expression in Peripheral Blood of Breast Cancer Patients and Breast Cancer Cell Lines.

Biomark Cancer 2016 28;8:57-63. Epub 2016 Apr 28.

Molecular Biology Department, Pasteur Institute of Iran, Tehran, Iran.

Detection of cytokeratin-19 (CK19) expression as an epithelial-specific marker in circulating tumor cells (CTCs) of breast cancer patients can be important for diagnostic purposes. Comparison of CK19 expression in breast cancer cell lines can indicate that expression of this marker is different in various breast cancer cell lines based on their category. Thirty-five breast cancer patients were evaluated for detection of CK19 mRNA in their peripheral blood using CK19-specific primers and a nested reverse transcriptase polymerase chain reaction (RT-PCR) technique. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S38229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852760PMC
May 2016
6 Reads

Role of Biomarkers in the Development of PARP Inhibitors.

Biomark Cancer 2016 9;8(Suppl 1):15-25. Epub 2016 Mar 9.

Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Defects in DNA repair lead to genomic instability and play a critical role in cancer development. Understanding the process by which DNA damage repair is altered or bypassed in cancer may identify novel therapeutic targets and lead to improved patient outcomes. Poly(adenosine diphosphate-ribose) polymerase 1 (PARP1) has an important role in DNA repair, and novel therapeutics targeting PARP1 have been developed to treat cancers with defective DNA repair pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S36679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786099PMC
March 2016
22 Reads

Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel.

Biomark Cancer 2016 16;8:43-56. Epub 2016 Mar 16.

Department of Biophysics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.

Conventional treatment for advanced ovarian cancer is an initial debulking surgery followed by chemotherapy combination of carboplatin and paclitaxel. Despite initial high response, three-fourths of these women experience disease recurrence with a dismal prognosis. Patients with advanced-stage ovarian cancer who underwent cytoreductive surgery were enrolled and tissue samples were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S35775DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795487PMC
March 2016
6 Reads
2 Citations

Novel Molecular Markers for Breast Cancer.

Biomark Cancer 2016 13;8:25-42. Epub 2016 Mar 13.

Department of Pathology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC, USA.

The use of molecular biomarkers assures that breast cancer (BC) patients receive optimal treatment. Established biomarkers, such as estrogen receptor, progesterone receptor, HER2, and Ki67, have been playing significant roles in the subcategorization of BC to predict the prognosis and decide the specific therapy to each patient. Antihormonal therapy using 4-hydroxytamoxifen or aromatase inhibitors have been employed in patients whose tumor cells express hormone receptors, while monoclonal antibody to HER2 has been administered to HER2-positive BCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S38394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790586PMC
March 2016
2 Reads

A Unique Procedure to Identify Cell Surface Markers Through a Spherical Self-Organizing Map Applied to DNA Microarray Analysis.

Biomark Cancer 2016 3;8:17-23. Epub 2016 Mar 3.

Laboratory of Nano-Biotechnology, Department of Medical Bioengineering Science, Graduate School of Natural Science and Biotechnology, Okayama University, Kita-ku, Okayama, Japan.

To identify cell-specific markers, we designed a DNA microarray platform with oligonucleotide probes for human membrane-anchored proteins. Human glioma cell lines were analyzed using microarray and compared with normal and fetal brain tissues. For the microarray analysis, we employed a spherical self-organizing map, which is a clustering method suitable for the conversion of multidimensional data into two-dimensional data and displays the relationship on a spherical surface. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S33542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778852PMC
March 2016
7 Reads
1 Citation

Imaging Biomarkers in Immunotherapy.

Biomark Cancer 2016 25;8(Suppl 2):1-13. Epub 2016 Feb 25.

Department of Radiology, McMaster University, Hamilton, ON, Canada.; Department of Medicine, McMaster University, Hamilton, ON, Canada.

Immune-based therapies have been in use for decades but recent work with immune checkpoint inhibitors has now changed the landscape of cancer treatment as a whole. While these advances are encouraging, clinicians still do not have a consistent biomarker they can rely on that can accurately select patients or monitor response. Molecular imaging technology provides a noninvasive mechanism to evaluate tumors and may be an ideal candidate for these purposes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S31805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768940PMC
March 2016
1 Read

The VA Point-of-Care Precision Oncology Program: Balancing Access with Rapid Learning in Molecular Cancer Medicine.

Biomark Cancer 2016 29;8:9-16. Epub 2016 Feb 29.

Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.; Department of Statistics, Stanford University, Stanford, CA, USA.

The Department of Veterans Affairs (VA) recognized the need to balance patient-centered care with responsible creation of generalizable knowledge on the effectiveness of molecular medicine tools. Embracing the principles of the rapid learning health-care system, a new clinical program called the Precision Oncology Program (POP) was created in New England. The POP integrates generalized knowledge about molecular medicine in cancer with a database of observations from previously treated veterans. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.4137/BIC.S37548
Publisher Site
http://dx.doi.org/10.4137/BIC.S37548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772906PMC
March 2016
5 Reads

Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers.

Biomark Cancer 2016 11;8(Supple 1):1-14. Epub 2016 Feb 11.

Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Significant advances in our knowledge of cancer genomes are rapidly changing the way we think about tumor biology and the heterogeneity of cancer. Recent successes in genomically-guided treatment approaches accompanied by more sophisticated sequencing techniques have paved the way for deeper investigation into the landscape of genomic rearrangements in cancer. While considerable research on solid tumors has focused on point mutations that directly alter the coding sequence of key genes, far less is known about the role of somatic rearrangements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S34417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756769PMC
February 2016
3 Reads

SIGNALING PATHWAYS AS BIOMARKERS.

Biomark Cancer 2015 14;7(Suppl 2):33-5. Epub 2016 Feb 14.

Director of Immunology & Project Management Kiromic Biopharma, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S37778DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755699PMC
February 2016
6 Reads

Circulating Neutrophil MicroRNAs as Biomarkers for the Detection of Lung Cancer.

Biomark Cancer 2016 24;8:1-7. Epub 2016 Jan 24.

Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.

Peripheral neutrophils are the predominant circulating leukocytes and an important component of innate and adaptive immune systems, which is a primary defense against cancer. MicroRNAs (miRNAs) can modulate neutrophil functions and play important roles in cancer pathogenesis by regulating neutrophil gene expression. To investigate if assessment of differential miRNA levels of peripheral neutrophils has the potential for diagnosis of non-small-cell lung cancer (NSCLC), we examine neutrophils of 15 patients with stage I NSCLC and 15 smokers without cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S37333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725606PMC
January 2016
2 Reads

Simultaneous Underexpression of let-7a-5p and let-7f-5p microRNAs in Plasma and Stool Samples from Early Stage Colorectal Carcinoma.

Biomark Cancer 2015 12;7(Suppl 1):39-48. Epub 2016 Jan 12.

Department of Pathology, Faculty of Medicine, The University of Helsinki, Helsinki, Finland.

Colorectal cancer (CRC) is the third most common malignancy and the second most common cause of cancer death worldwide. Early detection of CRC can improve patient survival rates; thus, the identification of noninvasive diagnostic markers is urgently needed. MicroRNAs (miRNAs) have extensive potential to diagnose several diseases, including cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S25252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711391PMC
January 2016
17 Reads

Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy.

Biomark Cancer 2015 17;7:69-76. Epub 2015 Dec 17.

Translational Genomics Research Institute, Phoenix, AZ, USA.

Purpose: Current first-line chemotherapy for patients with metastatic adrenocortical cancer (ACC) includes doxorubicin, etoposide, cisplatin, and mitotane with a reported response rate of only 23.2%. New therapeutic leads for patients with refractory tumors are needed; there is no standard second-line treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S34292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686344PMC
December 2015

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells.

Biomark Cancer 2015 15;7(Suppl 2):25-32. Epub 2015 Dec 15.

Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Acquired resistance to targeted inhibitors remains a major, and inevitable, obstacle in the treatment of oncogene-addicted cancers. Newer-generation inhibitors may help overcome resistance mutations, and inhibitor combinations can target parallel pathways, but durable benefit to patients remains elusive in most clinical scenarios. Now, recent studies suggest a third approach may be available in some cases-exploitation of oncogene overexpression that may arise to promote resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S29326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681422PMC
December 2015
7 Reads

Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar.

Biomark Cancer 2015 29;7:63-7. Epub 2015 Nov 29.

Faculty of Health and Social Care Sciences, Kingston University and St George's University of London, UK. ; Academic Health System (AHS), Hamad Medical Corporation (HMC), Doha, Qatar.

Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML), there is a high degree of resistance. Alpha- 1-acid glycoprotein may reduce drug efficacy through its ability to interact with IM and blocks it from reaching its target, while protein glycoprotein (PGP) may reduce the intracellular concentration of the drug via an active pump mechanism. We thus investigated the correlation between AGP and PGP levels and the resistance/response to treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S31427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664201PMC
December 2015
22 Reads

Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer.

Biomark Cancer 2015 2;7(Suppl 1):29-37. Epub 2015 Nov 2.

Department of Oncology, Drug Discovery Division, Southern Research Institute, Birmingham, AL, USA.

Colon cancer development and malignant progression are driven by genetic and epigenetic alterations in tumor cells and by factors from the tumor microenvironment. Cancer cells become reliant on the activity of specific oncogenes and on prosurvival and proliferative signals they receive from the abnormal environment they create and reside in. Accordingly, the response to anticancer therapy is determined by genetic and epigenetic changes that are intrinsic to tumor cells and by the factors present in the tumor microenvironment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S25247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631158PMC
November 2015
41 Reads
2 Citations

Associations of the A66G Methionine Synthase Reductase Polymorphism in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Biomark Cancer 2015 29;7(Suppl 1):21-8. Epub 2015 Oct 29.

Genotoxicity Laboratory, Toxicology Division, Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

Inconsistency in the reported associations between the A66G polymorphism in the methionine synthase reductase (MTRR) gene and colorectal cancer (CRC) prompted a meta-analysis, so that we could obtain a more precise estimate. Databases searches of the published literature yielded 20 case-control studies from 17 articles (8,371 cases and 12,574 controls). We calculated pooled odds ratios (ORs) and 95% confidence intervals in three genetic comparisons (A allele, G allele, and A/G genotype). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S25251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627415PMC
November 2015
12 Reads
1 Citation

Biomarkers of Angiogenesis in Colorectal Cancer.

Biomark Cancer 2015 27;7(Suppl 1):13-9. Epub 2015 Oct 27.

The Medstar Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Columbus, OH, USA.

Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 10% of all new cancer diagnoses. Angiogenesis is a tightly regulated process that is mediated by a group of angiogenic factors such as vascular endothelial growth factor and its receptors. Given the widespread use of antiangiogenic agents in CRC, there has been considerable interest in the development of methods to identify novel markers that can predict outcome in the treatment of this disease with angiogenesis inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S25250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624093PMC
November 2015
6 Reads
6 Citations

Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies.

Biomark Cancer 2015 22;7:57-61. Epub 2015 Oct 22.

Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark. ; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Soluble cancer-related protein biomarker levels may be increased in subjects without findings at large bowel endoscopy performed due to symptoms associated with colorectal cancer. The present study focused on a possible association between increased biomarker levels in such subjects and subsequent development of malignant diseases. In a major study of 4,990 subjects undergoing large bowel endoscopy, 691 were without pathology and comorbidity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S31330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620935PMC
November 2015
13 Reads

Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries.

Biomark Cancer 2015 4;7(Suppl 2):19-24. Epub 2015 Oct 4.

Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.

Ameloblastoma is an odontogenic neoplasm whose molecular pathogenesis has only recently been elucidated. The discovery of recurrent activating mutations in FGFR2, BRAF, and RAS in a large majority of ameloblastomas has implicated dysregulation of MAPK pathway signaling as a critical step in the pathogenesis of this tumor. Some degree of controversy exists regarding the role of mutations affecting the sonic hedgehog (SHH) pathway, specifically Smoothened (SMO), which have been postulated to serve as either an alternative pathogenetic mechanism or secondary mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S29329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597444PMC
October 2015
1 Read

Microparticles as Biomarkers of Blood Coagulation in Cancer.

Biomark Cancer 2015 1;7:51-6. Epub 2015 Oct 1.

First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan.

Cancer is associated with hypercoagulopathy and increased risk of thrombosis. This negatively influences patient morbidity and mortality. Cancer is also frequently complicated by the development of venous thromboembolism (VTE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BIC.S30347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592056PMC
October 2015
2 Reads